In this issue:
- P3-GemOx: novel immunochemotherapy for NKTL
- RBAC then venetoclax in older patients with high-risk MCL
- MRD-guided therapy for CLL
- Acalabrutinib-obinutuzumab vs. chemoimmunotherapy in treatment-naive CLL
- Nivolumab vs. brentuximab vedotin, with AVD, in older advanced-stage classical Hodgkin lymphoma
- Anti-CD7 allogeneic WU-CART-007 for relapsed/ refractory T-cell malignancies
- NZ MM patients have inferior outcomes than Australians
- Belantamab mafodotin dose modifications for ocular events
- Dexamethasone-sparing regimen in frail newly diagnosed MM
- Long-term remission and survival after cilta-cel for relapsed/refractory MM
Please login below to download this issue (PDF)